PLOS ONE | DOI:10.1371/journal.pone.0142290 November 9, 2015; 1 / 16
6th edition, 2010. | Published in collaboration with World Health Organisation and Clinton Health Access Initiative.
Prepared as an outcome of ICMR Subcommittee on Non Hodgkin’s Lymphoma (High Grade) | This consensus document on management of non- hodgkin’s lymphoma – high grade summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molec...ular markers and research questions. It also interweaves clinical, biochemical and epidemiological studies.
more
The essential medicines are those that meet the priority needs of the healthcare of the population. While reviewing the 5th edition of the essential Medicines, special attention focused on the health sector policy. Indeed, medicines play an important role in protecting, maintaining and restoring th...e peoples’ health and credibility of health facilities. Their availability is a fundamental aspect of primary health care as defined in different declarations including Alma-Ata of 1978.
more
with recommended essential medicines for common diseases in patients in Stockholm County Council (Healthcare Region), Sweden
Les périodes périnatale et néonatale constituent des moments critiques dans la vie des mères et des nouveau-nés. En effet, pendant ces périodes, des complications obstétricales, foetales et néonatales surviennent entrainant des mort-nés, des décès néonatals et des possibilités d’incap...acités si l’enfant survit. Les présentes directives nationales de santé des nouveau-nés, définies comme des lignes de conduite données par l’Autorité, en l’occurrence le Ministre de la Santé, visent à prévenir, dépister et prendre en charge ces complications en vue de d’améliorer la qualité des soins et de réduire la morbidité et la mortalité foetales et néonatales, ainsi que les handicaps à moyen ou long terme chez l’enfant. Les directives se focalisent principalement sur la période autour de l’accouchement, les premières heures et les sept (7) premiers jours de vie de l’enfant.
Pour les rendre opérationnelles, il faudrait
more
Tropical Medicine and International Health volume 21 no 1 pp 101-107 january 2016
This volume presents the complex patterns of cancer incidence and death around the world and evidence on effective and cost-effective ways to control cancers. The Disease Control Priorities Volume 3 evaluation of cancer will indicate where cancer treatment is ineffective and wasteful, and offer alte...rnative cancer care packages that are cost-effective and suited to low-resource settings.
Disease Control Priorities, Third Edition: Volume 3
more
The document covers: introduction on contact tracing in the Ebola response; general considerations for contact tracing; case definition; planning and preparation; personnel; implementation, and tools for contact tracing.
Petersen et al. Int J Ment Health Syst (2016) 10:30 DOI 10.1186/s13033-016-0060-z
A guidebook intended for use by first responders
during the initial phase of a transportation incident
involving dangerous goods/hazardous materials
Un guide destiné aux premiers intervenants sur les mesures
d’urgence au cours de la phase initiale d’un incident de transport
mettant en cause des marchandises dangereuses
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of key DR-TB drugs, using manufacturer responses to s...tandardised questionnaires and the Global TB Drug Facility website.
more
This report provides an update on the key facets of HIV treatment access, including the latest HIV treatment guidelines from World Health Organization (WHO), an overview on pricing for first-line, second-line, and salvage regimens, and a summary of the opportunities for – and threats to – expand...ing access to affordable antiretroviral therapy (ART).
The report is supplemented by 11 drug profiles that contain more detailed information on pricing trends and patent barriers for key antiretroviral drugs and fixed-dose combinations. Also included is an annex of conditions that define eligibility for reduced prices from 15 pharmaceutical companies.
more
Standard Treatment Guidelines